<?xml version="1.0"?><rss version="2.0"><channel><title>antibodies - Latest News</title><link>http://news.prlog.org/tag/antibodies/</link><description>antibodies - Latest News (Press Releases) - Read news before it's news</description><language>en-us</language><ttl>3600</ttl>
<item><title>ImmunoReagents Enters Distributorship Agreement with Abyntek Biopharma of Spain</title><link>http://www.prlog.org/12074899-immunoreagents-enters-distributorship-agreement-with-abyntek-biopharma-of-spain.html</link><description>ImmunoReagents, a manufacturer of high quality polyclonal antibodies and reagents used by researchers, pharmaceutical and biotechnology companies, has announced Abyntek Biopharma as its new distributor in Spain.</description></item>
<item><title>ImmunoReagents Signs French Distributorship Agreement with Ozyme</title><link>http://www.prlog.org/12051733-immunoreagents-signs-french-distributorship-agreement-with-ozyme.html</link><description>ImmunoReagents, a manufacturer of high quality polyclonal antibodies and reagents used by researchers, pharmaceutical and biotechnology companies, has announced the appointment of Ozyme as its new distributor in France.</description></item>
<item><title>ImmunoReagents Signs Swiss Distributorship Agreement with LabForce Ag</title><link>http://www.prlog.org/12045634-immunoreagents-signs-swiss-distributorship-agreement-with-labforce-ag.html</link><description>ImmunoReagents, a manufacturer of high quality polyclonal antibodies and reagents used by researchers, pharmaceutical and biotechnology companies, has announced the appointment of LabForce as its new distributor in Switzerland.</description></item>
<item><title>tebu-bio collaborates with Biosensis to distribute their validated research antibodies in Europe</title><link>http://www.prlog.org/12045346-tebu-bio-collaborates-with-biosensis-to-distribute-their-validated-research-antibodies-in-europe.html</link><description>tebu-bio announces today a distributor agreement with research antibody maker Biosensis bringing innovative tools for Life Sciences to European researchers</description></item>
<item><title>Peter Senter, Ph.D., to Deliver Opening Keynote at Cancer Biologics 2013</title><link>http://www.prlog.org/12040350-peter-senter-phd-to-deliver-opening-keynote-at-cancer-biologics-2013.html</link><description>CHI’s 4th Annual Cancer Biologics, February 13-15, 2013, San Francisco, CA</description></item>
<item><title>Immune Responses in Tumor Microenvironment Workshop (Jan 30, 2013 in San Diego)</title><link>http://www.prlog.org/12027908-immune-responses-in-tumor-microenvironment-workshop-jan-30-2013-in-san-diego.html</link><description>GTC is proud to present the Immune Responses in Tumor Microenvironment Workshop on Jan 30, 2013 in San Diego, CA.</description></item>
<item><title>Ronald Swanson to Speak at ImmunoTherapeutics &amp; ImmunoMonitoring Jan 31–Feb 1, 2013</title><link>http://www.prlog.org/12027904-ronald-swanson-to-speak-at-immunotherapeutics-immunomonitoring-jan-31feb-1-2013.html</link><description>Ronald Swanson, Senior Director, Janssen R&amp;D Will Give a Featured Presentation at the 5th ImmunoTherapeutics &amp; ImmunoMonitoring Conference (Jan 31 – Feb 1, 2013 in San Diego, CA)</description></item>
<item><title>ImmunoReagents Signs Indian Distributorship Agreement with Labex Corporation.</title><link>http://www.prlog.org/11994177-immunoreagents-signs-indian-distributorship-agreement-with-labex-corporation.html</link><description>ImmunoReagents, a manufacturer of high quality polyclonal antibodies used by researchers, pharmaceutical and biotechnology companies, has announced the appointment of Labex Corporation as its new distributor in India.</description></item>
<item><title>ImmunoReagents Signs South Korean Distributorship Agreement with Sungwoo Life Sciences.</title><link>http://www.prlog.org/11989510-immunoreagents-signs-south-korean-distributorship-agreement-with-sungwoo-life-sciences.html</link><description>ImmunoReagents, a manufacturer of high quality polyclonal antibodies used by researchers, pharmaceutical and biotechnology companies, has announced the appointment of Sungwoo Life Sciences as its new distributor in South Korea.</description></item>
<item><title>Understand FDA developments &amp; EU regulations for Biosimilars on 24th &amp; 25th September, London</title><link>http://www.prlog.org/11935684-understand-fda-developments-eu-regulations-for-biosimilars-on-24th-25th-september-london.html</link><description>Variations in global regulatory strategy for biosimilars outside Europe, Japan and the US</description></item>
<item><title>Immunogenicity Assessment and Clinical Relevance Conference, Part One at Immunogenicity Summit</title><link>http://www.prlog.org/11915103-immunogenicity-assessment-and-clinical-relevance-conference-part-one-at-immunogenicity-summit.html</link><description>“CHI's Immunogenicity Assessment and Clinical Relevance,” takes place on Oct. 10-11, 2012 in Bethesda, MD.</description></item>
<item><title>ImmunoReagents Signs Chinese Distributorship Agreement with AmyJet Scientific</title><link>http://www.prlog.org/11884739-immunoreagents-signs-chinese-distributorship-agreement-with-amyjet-scientific.html</link><description>(Raleigh, NC) -- ImmunoReagents, a manufacturer of high quality polyclonal antibodies used by researchers, pharmaceutical and biotechnology companies, has announced the appointment of AmyJet Scientific as its new distributor in China.</description></item>
<item><title>ImmunoReagents Announces Exclusive German Distribution Channel with BioLeague.</title><link>http://www.prlog.org/11861071-immunoreagents-announces-exclusive-german-distribution-channel-with-bioleague.html</link><description>ImmunoReagents, a manufacturer of high quality polyclonal antibodies used by researchers, pharmaceutical and biotechnology companies, has announced the appointment of Bioleague as its new distributor in Germany.</description></item>
<item><title>SMi’s inaugural ADC Summit, 23rd &amp; 24th May 2012, London</title><link>http://www.prlog.org/11859579-smis-inaugural-adc-summit-23rd-24th-may-2012-london.html</link><description>Consider novel linker strategy techniques to increase efficacy of ADC products</description></item>
<item><title>ImmunoReagents Announces Exclusive Japanese Distribution Channel with Funakoshi Ltd. Co.</title><link>http://www.prlog.org/11837094-immunoreagents-announces-exclusive-japanese-distribution-channel-with-funakoshi-ltd-co.html</link><description>ImmunoReagents, a manufacturer of high quality secondary antibodies used by researchers, pharmaceutical and biotechnology companies, has announced the appointment of Funakoshi as its new distributor for Japan.</description></item>
<item><title>“Indian Diagnostic &amp; Therapeutic Antibodies Market Report &amp; Forecast” added to ReportBuyer.com</title><link>http://www.prlog.org/11780236-indian-diagnostic-therapeutic-antibodies-market-report-forecast-added-to-reportbuyercom.html</link><description>New report: Indian Diagnostic &amp; Therapeutic Antibodies Market Report &amp; Forecast: 2011-2016</description></item>
<item><title>Cambridge Healthtech Institute Announces its Third Annual Cancer Biologics Conference</title><link>http://www.prlog.org/11763809-cambridge-healthtech-institute-announces-its-third-annual-cancer-biologics-conference.html</link><description>CHI’s Cancer Biologics conference is being held at the Molecular Med TRI-CON 2012 on February 21-23 at the Moscone in San Francisco.</description></item>
<item><title>Custom monoclonal antibody services</title><link>http://www.prlog.org/11762524-custom-monoclonal-antibody-services.html</link><description>Vrisko limited is now providing custom antibody services produced by the hybridoma technology. Our company has reached aggreement with leader biotechnology companies to provide the best monoclonal antibody services.</description></item>
<item><title>In Cell Art, Sanofi Pasteur and CureVac launch $33.1 million R&amp;D consortium</title><link>http://www.prlog.org/11724489-in-cell-art-sanofi-pasteur-and-curevac-launch-331-million-rd-consortium.html</link><description>In Cell Art, a biotechnology company specialising in the development of innovative vaccines and antibodies, has announced today the launch of a US$33.1 million research-and-development project — the RN Armor Vax Consortium.</description></item>
<item><title>2B Scientific Announce New Antibody, Reagent and Kit Supplier –IMGENEX</title><link>http://www.prlog.org/11682888-2b-scientific-announce-new-antibody-reagent-and-kit-supplier-imgenex.html</link><description>2B Scientific, a leading UK distributor of life science reagents now supplies antibodies, reagents and kits from IMGENEX Corporation.</description></item>
<item><title>Gold nuggets for biotechnology</title><link>http://www.prlog.org/11659522-gold-nuggets-for-biotechnology.html</link><description>While the gold price keeps setting new records, nanoparticles from pure gold are also gaining importance in biotechnology. Particular GmbH from Germany now uses a laser method to produce them with high purity and conjugate them with high efficiency.</description></item>
<item><title>Six Ways to Boost Your Immune System</title><link>http://www.prlog.org/11584626-six-ways-to-boost-your-immune-system.html</link><description>Part two of the article series on your immune system focuses in on changes that can occur as we age. It's important to know what can happen, and what can further weaken your immune system. Let's get to it.</description></item>
<item><title>You &amp; Your Immune System, Part 1</title><link>http://www.prlog.org/11580991-you-your-immune-system-part-1.html</link><description>And so begins my multi-part article on a very important subject: your immune system; the things inside you that attack foreign invaders and prevent disease from setting in. Before I get to the ways you can boost your own immunity,</description></item>
<item><title>Randox Life Sciences produce highly sensitive antibodies to a range of Drugs of Abuse targets</title><link>http://www.prlog.org/11561963-randox-life-sciences-produce-highly-sensitive-antibodies-to-range-of-drugs-of-abuse-targets.html</link><description>Randox Life Sciences has developed and manufactured a wide range of products including high quality, cost effective recombinant proteins, polyclonal antibodies and conjugates targeting drugs of abuse, steroids, hormones and biochemical markers.</description></item>
<item><title>Experience the Future of Biologics at CHI's PEGS - the essential protein engineering summit</title><link>http://www.prlog.org/11416642-experience-the-future-of-biologics-at-chis-pegs-the-essential-protein-engineering-summit.html</link><description>Featuring 12 conference programs within 4 streams focused on the current trends and science in antibody engineering and development (PEGSummit.com).</description></item>
<item><title>New Recombinant Antibody Fragments from Randox Life Sciences</title><link>http://www.prlog.org/11281095-new-recombinant-antibody-fragments-from-randox-life-sciences.html</link><description>Randox Life Sciences is a recognised primary manufacturer of high quality, cost-effective human recombinant proteins, recombinant antibody fragments and polyclonal and monoclonal antibodies to classic and novel targets.</description></item>
<item><title>Therapeutic Antibodies: Status, Strategies and Outlook</title><link>http://www.prlog.org/11218590-therapeutic-antibodies-status-strategies-and-outlook.html</link><description>Therapeutic antibodies are central to pharmaceutical development; needless to say, emphasis is continually on developing new methods and improving those already in place. Play an active role in the war against disease – register online today!</description></item>
<item><title>tebu-bio and Advanced Biotechnologies Inc. renew Distributor Agreement for 2011</title><link>http://www.prlog.org/11155913-tebu-bio-and-advanced-biotechnologies-inc-renew-distributor-agreement-for-2011.html</link><description>tebu-bio is pleased to announce the renewal of their agreement with Advanced Biotechnologies for the distribution of their products throughout Europe.</description></item>
<item><title>Activiomics signs technology agreement with UCB</title><link>http://www.prlog.org/11127760-activiomics-signs-technology-agreement-with-ucb.html</link><description>UCB seeking to understand cell signalling mechanisms of therapeutic antibodies enabling identification of biomarkers</description></item>
<item><title>AnaSpec Introduces Anti-MOG (1-125), Mouse Monoclonal</title><link>http://www.prlog.org/11067519-anaspec-introduces-anti-mog-1-125-mouse-monoclonal.html</link><description>Being the first in the industry to provide a whole suite of reagents and assay kits for the advancement of MS research, AnaSpec is pleased to announce the release of the mouse monoclonal Anti-MOG (1-125).</description></item>
<item><title>Parallels in Development of Monoclonal Antibodies and Therapeutic Vaccines Prompt Industry Optimism</title><link>http://www.prlog.org/11023527-parallels-in-development-of-monoclonal-antibodies-and-therapeutic-vaccines-prompt-industry-optimism.html</link><description>Although the therapeutic vaccine market has experienced a range of setbacks and disappointments, technological evolution should ultimately enable therapeutic vaccines to make similar commercial breakthroughs as monoclonal antibodies, notes Kalorama.</description></item>
<item><title>AbboMax announces the availability of new methyl- specific antibodies for the epigenetics research.</title><link>http://www.prlog.org/11013857-abbomax-announces-the-availability-of-new-methyl-specific-antibodies-for-the-epigenetics-research.html</link><description>AbboMax offers nine novel anti- histone H3 antibodies specific for a mono-, di-, or tri-methylated state of Lys4, Lys9, and Lys27 for the epigenetics research. .</description></item>
<item><title>Technological and Commercial Opportunities of Therapeutic Monoclonal Antibodies</title><link>http://www.prlog.org/10973013-technological-and-commercial-opportunities-of-therapeutic-monoclonal-antibodies.html</link><description>Bharatbook added a new report on &quot;Therapeutic Monoclonal Antibodies: World Market 2010-2025&quot; which gives the potential applications and prospects on worldwide Therapeutic Monoclonal Antibodies.</description></item>
<item><title>Oncology Leads Pharmaceutical Drug Development, reports Kalorama Information</title><link>http://www.prlog.org/10950866-oncology-leads-pharmaceutical-drug-development-reports-kalorama-information.html</link><description>Oncology has emerged as the third largest segment in drug treatment, largely due to the growth of adjunctive therapies and high-cost of effective biotherapy. Sales have increased from $30 billion in 2005 to $65 billion forecasted for 2010.</description></item>
<item><title>DNA Vaccination By 2015 Possible, says Kalorama Information Report</title><link>http://www.prlog.org/10936363-dna-vaccination-by-2015-possible-says-kalorama-information-report.html</link><description>Because DNA vaccines generate cell-mediated immunity, the hope is that they will be effective against difficult viruses, even in cases where standard vaccines have failed to work.</description></item>
<item><title>New Report Monoclonal Antibodies Market (2010 - 2015) Published By MarketsandMarkets</title><link>http://www.prlog.org/10896614-new-report-monoclonal-antibodies-market-2010-2015-published-by-marketsandmarkets.html</link><description>The global market for diagnostic and therapeutic market is expected to exceed $ 25 million market by the end of 2010. mAbs held the top 3 ranks among the top selling brands in 2008.</description></item>
<item><title>Introduction to Monoclonal Antibodies for Cancer Therapy Available through Bharatbook</title><link>http://www.prlog.org/10836697-introduction-to-monoclonal-antibodies-for-cancer-therapy-available-through-bharatbook.html</link><description>Bharatbook added a new report on &quot;Monoclonal Antibodies in Cancer Therapy: World Market Prospects 2010-2025&quot; explains how this market will develop, and where the opportunities will lie.</description></item>
<item><title>Highly specific monoclonal antibodies available from Randox Life Sciences</title><link>http://www.prlog.org/10821635-highly-specific-monoclonal-antibodies-available-from-randox-life-sciences.html</link><description>Randox Life Sciences is a recognised primary manufacturer of high quality, cost effective monoclonal antibodies to both classic and novel targets.</description></item>
<item><title>MedImmune: collaboration with Trellis strengthens RSV pipeline</title><link>http://www.prlog.org/10729004-medimmune-collaboration-with-trellis-strengthens-rsv-pipeline.html</link><description>MedImmune has agreed to license the rights to develop Trellis Bioscience's monoclonal antibody products for the treatment of respiratory syncytial virus (RSV).</description></item>
<item><title>Multiple sclerosis - still an unknown disease</title><link>http://www.prlog.org/10723645-multiple-sclerosis-still-an-unknown-disease.html</link><description>Multiple Sclerosis (MS) is a possibly the weakening ailment, where one’s immune system slowly deteriorates as the protective cover of one’s nerves worsens by each passing day.</description></item>
<item><title>World’s Most Comprehensive Nanoparticle Analysis System Unveiled At Global Biotech Event</title><link>http://www.prlog.org/10660584-worlds-most-comprehensive-nanoparticle-analysis-system-unveiled-at-global-biotech-event.html</link><description>Izon Science unveil latest breakthrough in nanoparticle analysis at 2010 BIO International Convention in Chicago</description></item>
<item><title>&quot;The Future of the Biologicals Market: Market overview, innovations and company profiles&quot; Published</title><link>http://www.prlog.org/10652464-the-future-of-the-biologicals-market-market-overview-innovations-and-company-profiles-published.html</link><description>New Pharmaceuticals research report from Business Insights is now available from Fast Market Research</description></item>
<item><title>New Market Report: Preclinical Development of Monoclonal Antibodies and Related Biologicals</title><link>http://www.prlog.org/10652426-new-market-report-preclinical-development-of-monoclonal-antibodies-and-related-biologicals.html</link><description>Recently published research from Business Insights, &quot;Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging technologies and new therapeutic candidates&quot;, is now available at Fast Market Research</description></item>
<item><title>Novus Biologicals launches first TMEM97 antibody on the market</title><link>http://www.prlog.org/10589696-novus-biologicals-launches-first-tmem97-antibody-on-the-market.html</link><description>Novus Biologicals, an international supplier of antibodies, biological products and materials to various scientific sectors, announce that they have launched the first TMEM97 antibody onto the market.</description></item>
<item><title>Novus Biologicals Enhances Stem Cell Product Offering</title><link>http://www.prlog.org/10516829-novus-biologicals-enhances-stem-cell-product-offering.html</link><description>Novus Biologicals, an international supplier of antibodies, biological products and materials to various scientific sectors</description></item>
<item><title>Novus Biologicals Launches New Histone Antibodies For DNA Repair Research</title><link>http://www.prlog.org/10515563-novus-biologicals-launches-new-histone-antibodies-for-dna-repair-research.html</link><description>Novus Biologicals, an international supplier of antibodies, biological products and materials to various scientific sectors, have launched new Histone antibodies for use in DNA repair research.</description></item>
<item><title>Novus Biologicals Launches New HIF Prolyl Hydroxylase Antibody</title><link>http://www.prlog.org/10514782-novus-biologicals-launches-new-hif-prolyl-hydroxylase-antibody.html</link><description>Novus Biologicals, an international supplier of antibodies, biological products and materials to various scientific sectors, have launched a new HIF Prolyl Hydroxylase antibody for use in research</description></item>
<item><title>Abcam and Cambridge Design Partnership Solve a Vial and Sticky Problem.</title><link>http://www.prlog.org/10474072-abcam-and-cambridge-design-partnership-solve-vial-and-sticky-problem.html</link><description>New approach automates verification, labelling and printing of high value products in tubes. A breakthrough in labelling technology promises a 450% increase in throughput for leading antibody supplier, Abcam plc.</description></item>
<item><title>Stapled Peptides Can Open New Routes To New Therapy Approaches For Multiple Diseases</title><link>http://www.prlog.org/10460622-stapled-peptides-can-open-new-routes-to-new-therapy-approaches-for-multiple-diseases.html</link><description>Bio-Synthesis, Inc. provides custom products for researchers and pharmaceutical companies</description></item>
<item><title>The Benefits of Anti-drug Antibodies</title><link>http://www.prlog.org/10426299-the-benefits-of-antidrug-antibodies.html</link><description>The new uses and benefits of anti-drug antibodies, examined by Bio-Synthesis, Inc.</description></item></channel></rss>